Rasmussen syndrome and CNS granulomatous disease with NOD2/CARD15 mutations

Neurology

Volumn 69, Issue 7, 2007, Pages 640-643

  Goyal, M ^a,c   Cohen, M L ^b   Bangert, B A ^b   Robinson, S ^a   Singer, N G ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CARBAMAZEPINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; ETANERCEPT; FLUORODEOXYGLUCOSE; IMMUNOGLOBULIN; INFLIXIMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; OXCARBAZEPINE; PHENYTOIN; PREDNISONE; TOPIRAMATE;

ANAMNESIS; ARTICLE; BACTERIUM CULTURE; BLAU SYNDROME; BRAIN BIOPSY; CASE REPORT; CEREBROSPINAL FLUID; CHILD; CLINICAL FEATURE; CROHN DISEASE; DRUG MEGADOSE; EPSTEIN BARR VIRUS; FEMALE; GENE MUTATION; GRANULOMATOSIS; GRANULOMATOUS INFLAMMATION; HEMISPHERECTOMY; HERPES SIMPLEX VIRUS; HUMAN; HYPOTHALAMUS; LUMBAR PUNCTURE; LYME DISEASE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; RASMUSSEN SYNDROME; SEIZURE; STATISTICAL SIGNIFICANCE; VITAL SIGN;

CHILD; DIAGNOSIS, DIFFERENTIAL; ENCEPHALITIS; FEMALE; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN;

EID: 34547885418     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000267429.89675.03     Document Type: Article

References (13)

1. Pardo CA, Vining EP, Guo L, Skolasky RL, Carson BS, Freeman JM. The pathology of Rasmussen syndrome: stages of cortical involvement and neuropathological studies in 45 hemispherectomies. Epilepsia 2004;45:516-526.
2. Hart YM, Andermann F, Robitaille Y, Laxer KD, Rasmussen T, Davis R. Double pathology in Rasmussen's syndrome: a window on the etiology? Neurology 1998;50:731-735.
3. Firlik KS, Adelson PD, Hamilton RL. Coexistence of a ganglioglioma and Rasmussen's encephalitis. Pediatr Neurosurg 1999;30:278-282.
4. Yacubian EM, Rosemberg S, Marie SK, Valério RM, Jorge CL, Cukiert A. Double pathology in Rasmussen's encephalitis: etiologic considerations. Epilepsia 1996;37:495-500.
5. Kumar R, Wani AA, Reddy J, Pal L, Pradhan S. Development of anaplastic ependymoma in Rasmussen's encephalitis: review of the literature and case report. Childs Nerv Syst 2006;22:416-419.
6. Ramaswamy V, Sinclair DB, Wheatley BM, Richer L, Snyder T. Epilepsia partialis continua: acute disseminated encephalomyelitis or Rasmussen's encephalitis? Pediatr Neurol 2005;32:341-345.
7. Lascelles K, Dean AF, Robinson RO. Rasmussen's encephalitis followed by lupus erythematosus. Dev Med Child Neurol 2002;44:572-574.
8. Wiendl H, Bien CG, Bernasconi P, et al. GluR3-antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 2001;57:1511-1514.
9. Mantegazza R, Bernasconi P, Baggi F, et al. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 2002;131:179-185.
10. Freeman JM. Rasmussen's syndrome: progressive autoimmune multi-focal encephalopathy. Pediatr Neurol 2005;32:295-299.
11. Kambe N, Nishikomori R, Kanazawa N. The cytosolic pattern-recognition receptor Nod2 and inflammatory granulomatous disorders. J Dermatol Sci 2005;39:71-80.
12. Sterka D Jr, Rati DM, Marriott I. Functional expression of NOD2, a novel pattern recognition receptor for bacterial motifs, in primary murine astrocytes. Glia 2006;53:322-330.
13. Bien CG, Elger CE, Wiendl H. Advances in pathogenic concepts and therapeutic agents in Rasmussen's encephalitis. Expert Opin Invest Drugs 2002;11:981-989.